Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Bio-Techne (TECH) EBIAT (2016 - 2026)

Bio-Techne has reported EBIAT over the past 17 years, most recently at $38.0 million for Q4 2025.

  • For Q4 2025, EBIAT rose 8.94% year-over-year to $38.0 million; the TTM value through Dec 2025 reached $81.1 million, down 48.71%, while the annual FY2025 figure was $73.4 million, 56.34% down from the prior year.
  • EBIAT for Q4 2025 was $38.0 million at Bio-Techne, roughly flat from $38.2 million in the prior quarter.
  • Over five years, EBIAT peaked at $89.7 million in Q3 2022 and troughed at -$17.7 million in Q2 2025.
  • A 5-year average of $46.4 million and a median of $47.4 million in 2021 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: skyrocketed 313.87% in 2022 and later crashed 143.55% in 2025.
  • Year by year, EBIAT stood at $72.1 million in 2021, then tumbled by 30.61% to $50.0 million in 2022, then plummeted by 45.08% to $27.5 million in 2023, then grew by 27.03% to $34.9 million in 2024, then grew by 8.94% to $38.0 million in 2025.
  • Business Quant data shows EBIAT for TECH at $38.0 million in Q4 2025, $38.2 million in Q3 2025, and -$17.7 million in Q2 2025.